AbbVie Stock Forecast for 2022 - 2025 - 2030

Updated on 05/28/2022

Stock Rating
6 / 10
Price Target
$167.75
Consensus
Outperform
Upside
11.83%
Analysts
19
Stock Rating
9
Upside
11.83%
Analysts
19
Price Target
$167.75

AbbVie's stock is projected to advance by 11.83% from the previous closing price if it reaches the average target of $167.75 by the year's end, as nineteen reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $200.00 and a low-end estimate of $125.00. Even if you are not interested in ABBV stock, it is still imperative to be aware of its competitors.

$167.75

11.83% Upside

Outperform
Outperform

AbbVie Fair Value Forecast for 2022 - 2025 - 2030

In the past three years, AbbVie's Fair Value has seen a tremendous growth rate, increasing from $85.59 to $137.41 – an increase of 60.56%. For next year, the 23.00 analysts predict earnings per share of $151.59, which would mean an increase of 10.31%. Over the next nine years, the pros' prediction is Fair Value of $154.94, which would mean a 9-year growth forecast of 12.76%.

2022 Fair Value Forecast
$151.59
2023 Fair Value Forecast
$129.95
2024 Fair Value Forecast
$129.73
2025 Fair Value Forecast
$140.77
2026 Fair Value Forecast
$148.13
2027 Fair Value Forecast
$152.13
2028 Fair Value Forecast
$157.32
2029 Fair Value Forecast
$157.76
2030 Fair Value Forecast
$154.94
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 12
$181.09 $187.12 2.71% 16
LLY Stock Forecast Eli Lilly and Outperform 16
$323.48 $281.95 -0.77% 12
AZN Stock Forecast AstraZeneca PLC Outperform 18
£105.80 £136.08 37.87% 13
ABT Stock Forecast Abbott Laboratories Outperform 14
$116.69 $141.24 19.98% 19
OR Stock Forecast L'Oréal Outperform 18
307.45€ 331.87€ 28.48% 14

AbbVie Revenue Forecast for 2022 - 2025 - 2030

In the past three years, AbbVie's Revenue has seen a tremendous growth rate, increasing from $32.75B to $56.20B – an increase of 71.58%. For next year, the 19.00 analysts predict earnings per share of $59.61B, which would mean an increase of 6.07%. Over the next nine years, the pros' prediction is Revenue of $63.93B, which would mean a 9-year growth forecast of 13.76%.

2022 Rev Forecast
$59.61B
2023 Rev Forecast
$55.93B
2024 Rev Forecast
$56.47B
2025 Rev Forecast
$58.95B
2026 Rev Forecast
$61.80B
2027 Rev Forecast
$63.60B
2028 Rev Forecast
$65.34B
2029 Rev Forecast
$65.24B
2030 Rev Forecast
$63.93B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$76.14 $76.69 5.07% 16
AMGN Stock Forecast Amgen Hold 7
$255.26 $246.46 -2.06% 13
ABI Stock Forecast Anheuser-Busch InBev SA/NV Outperform 0
55.86€ 76.71€ 18.98% 16

AbbVie Dividend per Share Forecast for 2022 - 2025 - 2030

AbbVie's DPS has increased by 34.43% in the last three years, going from $3.95 to $5.31. In the next year, analysts expect DPS to reach an unimpressive $5.71 – an increase of 7.53%. For the next nine years, the forecast is for DPS to grow by 15.44%.

2022 DPS Forecast
$5.71
2023 DPS Forecast
$6.00
2024 DPS Forecast
$6.17
2025 DPS Forecast
$6.50
2026 DPS Forecast
$6.93
2027 DPS Forecast
$6.79
2028 DPS Forecast
$6.13
2029 DPS Forecast
$6.13
2030 DPS Forecast
$6.13
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
GSK Stock Forecast GlaxoSmithKline Outperform 16
£17.33 £16.08 3.87% 11
MMM Stock Forecast 3M Hold 18
$149.51 $188.41 7.22% 17
GILD Stock Forecast Gilead Sciences Outperform 11
$64.80 $75.96 6.48% 19

AbbVie Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's Free Cash Flow has grown by 71.94%, from $12.79B to $21.99B. For the next year, analysts are expecting Free Cash Flow to reach an unimpressive $23.98B – an increase of 9.04%. Over the next nine years, experts predict that Free Cash Flow will grow by 26.59%.

2022 FCF Forecast
$23.98B
2023 FCF Forecast
$23.54B
2024 FCF Forecast
$22.89B
2025 FCF Forecast
$24.83B
2026 FCF Forecast
$26.28B
2027 FCF Forecast
$27.04B
2028 FCF Forecast
$27.44B
2029 FCF Forecast
$27.33B
2030 FCF Forecast
$27.84B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BDX Stock Forecast Becton, Dickinson and Outperform 17
$256.46 $270.20 11.13% 3
BAYN Stock Forecast Bayer Outperform 16
66.58€ 67.79€ 14.15% 14
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.79k ¥0.00 18.73% 0

AbbVie Net Income Forecast for 2022 - 2025 - 2030

In the past three years, AbbVie's Net Income has significantly grown, increasing from $5.69B to $11.54B – a growth of 102.95%. The next year looks extremely promising for AbbVie, with analysts predicting Net Income of $24.99B – an increase of 116.56%. Over the next nine years, experts anticipate that ABBV's Net Income will grow at a rate of 106.6%.

2022 NI Forecast
$24.99B
2023 NI Forecast
$21.29B
2024 NI Forecast
$21.25B
2025 NI Forecast
$22.87B
2026 NI Forecast
$23.91B
2027 NI Forecast
$24.17B
2028 NI Forecast
$24.72B
2029 NI Forecast
$24.54B
2030 NI Forecast
$23.85B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥2.83k ¥0.00 41.37% 0
BAX Stock Forecast Baxter International Outperform 17
$76.16 $89.29 18.17% 3
ALC Stock Forecast Alcon Outperform 0
CHF79.00 CHF0.00 15.3% 14

AbbVie EBITDA Forecast for 2022 - 2025 - 2030

In the past three years, AbbVie's EBITDA has seen a tremendous increase, going from $13.69B to $28.05B – an increase of 104.92%. Next year, analysts are expecting EBITDA to reach $31.73B – an increase of 13.12%. Over the next nine years, the forecast is for EBITDA to grow by 13.19%.

2022 EBITDA Forecast
$31.73B
2023 EBITDA Forecast
$27.70B
2024 EBITDA Forecast
$27.42B
2025 EBITDA Forecast
$28.53B
2026 EBITDA Forecast
$31.22B
2027 EBITDA Forecast
$31.94B
2028 EBITDA Forecast
$33.00B
2029 EBITDA Forecast
$32.39B
2030 EBITDA Forecast
$31.75B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BIIB Stock Forecast Biogen Outperform 11
$206.20 $287.21 10.33% 24
4503 Stock Forecast Astellas Pharma Outperform 0
¥1.80k ¥0.00 33.33% 0
BEI Stock Forecast Beiersdorf Outperform 16
95.06€ 102.71€ 12.56% 13

AbbVie EBIT Forecast for 2022 - 2025 - 2030

In the last three years, AbbVie's EBIT has grown by 63.79%, rising from $11.92B to $19.53B. For next year, analysts predict earnings per share of $30.79B, which would mean an increase of 57.65%. Over the next nine years, experts predict that AbbVie's EBIT will grow at a rate of 60.72%.

2022 EBIT Forecast
$30.79B
2023 EBIT Forecast
$26.78B
2024 EBIT Forecast
$26.64B
2025 EBIT Forecast
$28.40B
2026 EBIT Forecast
$30.12B
2027 EBIT Forecast
$31.25B
2028 EBIT Forecast
$32.46B
2029 EBIT Forecast
$32.42B
2030 EBIT Forecast
$31.39B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
HZNP Stock Forecast Horizon Therapeutics Public Buy 0
$86.60 $0.00 61.66% 8
4452 Stock Forecast Kao Outperform 18
¥6.11k ¥0.00 -1.75% 0
GMAB Stock Forecast Genmab A/S Outperform 0
kr2.22k kr2.84k 23.82% 13

AbbVie EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the past three years, AbbVie's EPS has seen a tremendous growth rate, increasing from $7.91 to $12.70 – an increase of 60.56%. For next year, the 23.00 analysts predict earnings per share of $14.01, which would mean an increase of 10.31%. Over the next nine years, the pros' prediction is EPS of $14.32, which would mean a 9-year growth forecast of 12.76%.

2022 EPS Forecast
$14.01
2023 EPS Forecast
$12.01
2024 EPS Forecast
$11.99
2025 EPS Forecast
$13.01
2026 EPS Forecast
$13.69
2027 EPS Forecast
$14.06
2028 EPS Forecast
$14.54
2029 EPS Forecast
$14.58
2030 EPS Forecast
$14.32
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
INCY Stock Forecast Incyte Outperform 9
$77.19 $95.69 19.83% 10
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$80.97 $108.43 38.94% 9
4151 Stock Forecast Kyowa Kirin Outperform 18
¥3.25k ¥0.00 10.77% 0

© Copyright 2022 | Stock Forecast | All Rights Reserved